Last reviewed · How we verify
Efavirenz for the first 2 weeks
Efavirenz for the first 2 weeks is a Small molecule drug developed by University Hospital, Geneva. It is currently in Phase 1 development.
At a glance
| Generic name | Efavirenz for the first 2 weeks |
|---|---|
| Sponsor | University Hospital, Geneva |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Blood albumin decreased
- Cough
- Diarrhoea
- Blood sodium decreased
- Pain in extremity
- Nasopharyngitis
- Headache
- Haemoglobin decreased
- Syphilis
- Neutrophil count decreased
- Back pain
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efavirenz for the first 2 weeks CI brief — competitive landscape report
- Efavirenz for the first 2 weeks updates RSS · CI watch RSS
- University Hospital, Geneva portfolio CI
Frequently asked questions about Efavirenz for the first 2 weeks
What is Efavirenz for the first 2 weeks?
Efavirenz for the first 2 weeks is a Small molecule drug developed by University Hospital, Geneva.
Who makes Efavirenz for the first 2 weeks?
Efavirenz for the first 2 weeks is developed by University Hospital, Geneva (see full University Hospital, Geneva pipeline at /company/university-hospital-geneva).
What development phase is Efavirenz for the first 2 weeks in?
Efavirenz for the first 2 weeks is in Phase 1.
What are the side effects of Efavirenz for the first 2 weeks?
Common side effects of Efavirenz for the first 2 weeks include Upper respiratory tract infection, Blood albumin decreased, Cough, Diarrhoea, Blood sodium decreased, Pain in extremity.